281 related articles for article (PubMed ID: 31721316)
1. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
Heratizadeh A; Haufe E; Stölzl D; Abraham S; Heinrich L; Kleinheinz A; Wollenberg A; Weisshaar E; Augustin M; Wiemers F; Zink A; von Kiedrowski R; Hilgers M; Worm M; Pawlak M; Sticherling M; Fell I; Handrick C; Schäkel K; Staubach-Renz P; Asmussen A; Schwarz B; Bell M; Effendy I; Bieber T; Homey B; Gerlach B; Tchitcherina E; Stahl M; Schwichtenberg U; Rossbacher J; Buck P; Mempel M; Beissert S; Biedermann T; Weidinger S; Schmitt J; Werfel T;
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1263-1272. PubMed ID: 31721316
[TBL] [Abstract][Full Text] [Related]
2. Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany.
Weisshaar E; Bentz P; Apfelbacher C; Haufe E; Heinrich L; Heratizadeh A; Abraham S; Harder I; Kleinheinz A; Wollenberg A; Schäkel K; Wiemers F; Ertner J; Augustin M; Wildberger J; Von Kiedrowski R; Worm M; Zink A; Effendy I; Asmussen A; Pawlak M; Sticherling M; Hilgers M; Handrick C; Quist S; Schwarz B; Bell M; Staubach-Renz P; Hong-Weldemann SH; Homey B; Brücher JJ; Weidinger S; Werfel T; Schmitt J;
Acta Derm Venereol; 2023 Jan; 103():adv00854. PubMed ID: 36688701
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
4. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].
Haufe E; Abraham S; Heratizadeh A; Harder I; Zink A; Weisshaar E; Kleinheinz A; von Kiedrowski R; Worm M; Bell M; Wollenberg A; Neubert K; Staubach-Renz P; Hilgers M; Bieber T; Fell I; Homey B; Effendy I; Mempel M; Schäkel K; Beissert S; Weidinger S; Werfel T; Schmitt J
Hautarzt; 2018 Oct; 69(10):815-824. PubMed ID: 30191254
[TBL] [Abstract][Full Text] [Related]
5. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
Schmitt J; Abraham S; Trautmann F; Stephan V; Fölster-Holst R; Homey B; Bieber T; Novak N; Sticherling M; Augustin M; Kleinheinz A; Elsner P; Weidinger S; Werfel T
J Dtsch Dermatol Ges; 2017 Jan; 15(1):49-59. PubMed ID: 27862987
[TBL] [Abstract][Full Text] [Related]
6. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
[TBL] [Abstract][Full Text] [Related]
8. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
[TBL] [Abstract][Full Text] [Related]
9. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
[TBL] [Abstract][Full Text] [Related]
10. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.
Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA
Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910
[TBL] [Abstract][Full Text] [Related]
11. Status report on the atopic dermatitis registry TREATgermany.
Siegels D; Haufe E; Heinrich L; Werfel T; Weidinger S; Schmitt J;
Allergol Select; 2021; 5():274-286. PubMed ID: 34532636
[TBL] [Abstract][Full Text] [Related]
12. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
[TBL] [Abstract][Full Text] [Related]
15. Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
Clabbers J; Boesjes C; Spekhorst L; van Gisbergen MW; Maas E; Marshall J; Janssen R; Janssen M; Zuithoff N; Steijlen P; de Graaf M; van Geel M; de Bruin-Weller M; Gostyński A
J Allergy Clin Immunol; 2024 Apr; 153(4):1155-1161.e4. PubMed ID: 38272373
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
[TBL] [Abstract][Full Text] [Related]
17. AtopyReg
Stingeni L; Chiricozzi A; Calzavara-Pinton P; Napolitano M; Peris K; Schena D; Patruno C; Rossi M; Foti C; Fargnoli MC; Corazza M; Ferrucci SM; Pigatto PD; Romanelli M; Fabbrocini G; Girolomoni G; Passante M; Romita P; Esposito M; Schettini N; Marzano AV; Tonini G; Marietti R; Casciola G; Argenziano G; Hansel K;
Am J Clin Dermatol; 2024 Jan; 25(1):149-160. PubMed ID: 37725229
[TBL] [Abstract][Full Text] [Related]
18. Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry.
Pilz AC; Schielein MC; Schuster B; Heinrich L; Haufe E; Abraham S; Heratizadeh A; Harder I; Kleinheinz A; Wollenberg A; Wiemers F; Weisshaar E; Augustin M; von Kiedrowski R; Pawlak M; Schäkel K; Wildberger J; Hilgers M; Werfel T; Weidinger S; Schmitt J; Biedermann T; Zink A;
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):413-421. PubMed ID: 34743344
[TBL] [Abstract][Full Text] [Related]
19. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
